The company says it is unlikely to meet full-year guidance and has an 8-K on file, but no revised range. The formal update is not expected until late October.
FINANCIALMARKETS.COM | AFTERNOON EDITION
Boston Scientific has told investors it is unlikely to meet its full-year 2026 guidance following a cyberattack, and an 8-K addressing the matter is on file. What is not on file is a number.
No quantified revised revenue or earnings range has been disclosed. The language remains qualitative, and the company has deferred a formal update to its third-quarter results, expected around October 28.
That leaves roughly seven weeks in which the company's own guidance is disavowed and nothing has replaced it. For a business of Boston Scientific's size, that is an unusual state to leave estimates in. A guidance withdrawal without a replacement range gives the sell side nothing to anchor to, which in practice means published estimates drift apart rather than converge, and the dispersion itself becomes a source of volatility into the print.
There is a defensible reason for the delay. A cyberattack's revenue effect depends on how long specific systems were unavailable, what order flow was deferred rather than lost, and what remediation costs land in which quarter. A company that guessed at those numbers in September and revised again in October would be worse off than one that waited. Boston Scientific has effectively chosen accuracy over timeliness.
The cost of that choice falls on investors who have to size a position without knowing the magnitude. The information they do have is directional and one-sided. "Unlikely to meet" establishes a floor on the bad news and no ceiling.
October 28 is the date. The specific things to look for are whether the company separates the revenue effect from the remediation cost, whether any of the deferred activity is characterized as recoverable in the fourth quarter, and whether the 2026 shortfall is presented as affecting the 2027 base.